Testing a Personalize Medication Log for Patients With Lymphoma

Lymphoma Clinical Trial

Official title:

Testing a Personalize Medication Log for Patients With Lymphoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02370446
• Other study ID #: 15-008
• Status: Completed
• Phase: N/A
• First received: February 18, 2015
• Last updated: January 10, 2017
• Start date: January 2015
• Est. completion date: January 2017

Study information

• Verified date: January 2017
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to see if using the MedLog is helpful to patients. Since the investigators do not yet know if this MedLog is helpful, some patients will receive it and some will receive our standard of care. The investigators want to know whether providing patients with this additional information is helpful and if having this additional information about their treatment schedule has an effect on their quality of life.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 5
• Est. completion date: January 2017
• Est. primary completion date: January 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of lymphoma

• No prior treatment for lymphoma

• Scheduled to receive CHOP14 +/- Rituximab, CEOP 21, CHOPE or EPOCH +/- Rituximab

• Age 18 or older

• Able to speak and read English

Exclusion Criteria:

• Documented major psychopathology or cognitive impairment likely in the judgment of the research staff to interfere with the participation or completion of the protocol.

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Lymphoma

Intervention

Other:
• personalized medication log

• standard of care

Behavioral:
• questionnaires

• Cognitive Interview

Locations

Country	Name	City	State
United States	Memorial Sloan Kettering Cancer Center	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	patient satisfaction with medication log ( identified qualitatively through the process of cognitive interviewing and further measured with the satisfaction question on the Patient Satisfaction and Treatment Data Sheet)	as identified qualitatively through the process of cognitive interviewing and further measured with the satisfaction question on the Patient Satisfaction and Treatment Data Sheet	1 year	No
Secondary	changes in quality of life	before and during therapy, as measured by PROMIS, Distress Thermometer and FACT scores, and to evaluate adherence with oral treatment medications, as measured by the MMAS-8.	1 year	No

External Links

•   Memorial Sloan Kettering Cancer Center